Brand and Other Names:Rapaflo
- Classes: BPH, Alpha Blockers
Dosing & Uses
Dosage Forms & Strengths
Benign Prostatic Hyperplasia
8 mg PO qDay
Administration: Take with meal
CrCl <50 mL/min: Dose adjustment not necessary
CrCl 30-50 mL/min: 4 mg PO qDay
CrCl <30 mL/min: Contraindicated
Mild-to-moderate impairment (Child-Pugh class A or B): Dose adjustment not necessary
Severe Impairment: (Child-Pugh class C): Contraindicated (not studied)
Serious - Use Alternative
Significant - Monitor Closely
Retrograde ejaculation (28%)
Orthostatic hypotension (3%; increased in patients >65 years)
Nasal congestion (2%)
Skin and subcutaneous tissue disorders: Toxic skin eruption, purpura, skin rash, pruritus, urticaria
Hepatobiliary disorders: Jaundice, impaired hepatic function associated with increased transaminase values
Immune system disorders: Allergic-type reactions, not limited to skin reactions including angioedema
Genitourinary system: Priapism
Severe renal impairment (CrCl <30 mL/min)
Severe hepatic impairment (Child-Pugh Score >10)
Concomitant strong CYP3A4 inhibitors or P-glycoprotein inhibitors
Renal impairment, cataract surgery (potential risk of Intraoperative Floppy Iris Syndrome)
Rule out prostate cancer prior to treatment
Risk of orthostatic hypotension with or without syncope with first dose
Additive blood pressure lowering effects and symptomatic hypotension can result from concomitant administration of PDE-5 inhibitor (eg, sildenafil, tadalafil, vardenafil)
Use with caution in patients with mid-to-moderate hepatic impairment
Use with caution in the elderly (risk of hypotension)
Not indicated for use in women or children
Not for use as hypertensive
Pregnancy & Lactation
Pregnancy Category: B; not indicated in women
Lactation: Unknown if distributed in breast milk; not indicated in women
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Selective antagonist of postsynaptic alpha-1-adrenoceptors; blocking the alpha1A-adrenoreceptors in the smooth muscle of the prostate leads to relaxation of the smooth muscle in the bladder neck and prostate causing an improvement of urine flow and decreased symptom of BPH.
Time: 2.6 +/- 0.9 hr
Concentration: (8mg dose) 62 ng/mL
Half-Life: 13 +/- 8 hr
Protein Bound: 97%
Vd: 49.5 L
Clearance: 10 L/hr
Metabolism: glucuronidation, alcohol & aldehyde dehydrogenase, CYP3A4
Excretion: feces & urine
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs